International Journal of Cardiology
Volume 125, Issue 2 , Pages 209-215 , 10 April 2008

Coexistent chronic obstructive pulmonary disease and heart failure in the elderly

  • Margherita Padeletti

      Affiliations

    • Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY, United States
    • ,
  • Sanja Jelic

      Affiliations

    • Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY, United States
    • ,
  • Thierry H. LeJemtel

      Affiliations

    • Division of Cardiology, Tulane University School of Medicine, New Orleans, LA, United States
    • Corresponding Author InformationCorresponding author. Tulane University School of Medicine, Department of Medicine, Section of Cardiology, 1430 Tulane Avenue, SL-48, New Orleans, LA 70112-2699, United States. Tel.: +1 504 988 3806; fax: +1 504 988 4237.

References 

  1. Havranek EP, Masoudi FA, Westfall KA, et al. Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J. 2002;143:412–417
  2. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–1233
  3. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70
  4. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519
  5. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ. 2003;326:196
  6. Maggioni AP, Sinagra G, Opasich C, et al. Beta blockers in patients with congestive heart failure: guided use in clinical practice investigators. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart. 2003;89:299–305
  7. Grady KL, Halvey K. Quality of life in elderly heart failure patients. J Geriatr Cardiol. 2006;3:227–236
  8. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887–1894
  9. Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care. 2006;51:1120–1124
  10. Maciejewski ML, Perkins M, Li YF, et al. Utilization and expenditures of veterans obtaining primary care in community clinics and VA medical centers: an observational cohort study. BMC Health Serv Res. 2007;7:56
  11. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–441
  12. Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail. 2003;5:337–344
  13. Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:1290–1295
  14. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  15. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10:198–204
  16. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10:1–30
  17. Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J. 2004;147:1078–1084
  18. Ray P, Arthaud M, Birolleau S, et al. Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J Am Geriatr Soc. 2005;53:643–648
  19. Rutten FH, Cramer MJ, Zuithoff NP, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007;9:651–659
  20. Fleg JL, Morrell CH, Bos AG, et al. Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation. 2005;112:674–682
  21. Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A. 2005;102:5618–5623
  22. Hepple RT, Hagen JL, Krause DJ, Jackson CC. Aerobic power declines with aging in rat skeletal muscles perfused at matched convective O2 delivery. J Appl Physiol. 2003;94:744–751
  23. Elosua R, Bartali B, Ordovas JM, Corsi AM, Lauretani F, Ferrucci L. Association between physical activity, physical performance, and inflammatory biomarkers in an elderly population: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2005;60:760–767
  24. Gielen S, Adams V, Linke A, et al. Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. Eur J Cardiovasc Prev Rehabil. 2005;12:393–400
  25. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006;61:10–16
  26. Welle S, Brooks A, Thornton CA. Senescence-related changes in gene expression in muscle: similarities and differences between mice and men. Physiol Genomics. 2001;5:67–73
  27. Hamada K, Vannier E, Sacheck JM, et al. Senescence of human skeletal muscle impairs the local inflammatory cytokine response to acute eccentric exercise. FASEB J. 2005;19:264–266
  28. Ades PA, Ballor DL, Ashikaga T, Utton JL, Nair KS. Weight training improves walking endurance in healthy elderly persons. Ann Intern Med. 1996;124:568–572
  29. Menshikova EV, Ritov VB, Fairfull L, et al. Effects of exercise on mitochondrial content and function in aging human skeletal muscle. J Gerontol A Biol Sci Med Sci. 2006;61:534–540
  30. Kohut ML, McCann DA, Russell DW, et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun. 2006;20:201–209
  31. Starkweather AR. The effects of exercise on perceived stress and IL-6 levels among older adults. Biol Res Nurs. 2007;8:186–194
  32. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16:1335–1347
  33. Netz Y, Wu MJ, Becker BJ, Tenenbaum G. Physical activity and psychological well-being in advanced age: a meta-analysis of intervention studies. Psychol Aging. 2005;20:272–284
  34. Jeger RV, Jorg L, Rickenbacher P, et al. Benefit of outpatient cardiac rehabilitation in under-represented patient subgroups. J Rehabil Med. 2007;39:246–251
  35. Wielenga RP, Huisveld IA, Bol E, et al. Exercise training in elderly patients with chronic heart failure. Coron Artery Dis. 1998;9:765–770
  36. Leosco D, Rengo G, Iaccarino G, et al. Exercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulation. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1596–H1603Epub 2007 Jun 8
  37. Owen A, Croucher L. Effect of an exercise programme for elderly patients with heart failure. Eur J Heart Fail. 2000;2:65–70
  38. Pu CT, Johnson MT, Forman DE, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol. 2001;90:2341–2350
  39. Williams AD, Carey MF, Selig S, et al. Circuit resistance training in chronic heart failure improves skeletal muscle mitochondrial ATP production rate—a randomized controlled trial. J Card Fail. 2007;13:79–85
  40. Wisloff U, Stoylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation. 2007;115:3086–3094
  41. Demopoulos L, Yeh M, Gentilucci M, et al. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation. 1997;95:1764–1767
  42. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996;153:976–980
  43. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc. 1998;30:1467–1474
  44. Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis. 1991;143:9–18
  45. Probst VS, Troosters T, Pitta F, et al. Cardiopulmonary stress during exercise training in patients with COPD. Eur Respir J. 2006;27:1110–1118
  46. Mador MJ, Bozkanat E, Aggarwal A, Shaffer M, Kufel TJ. Endurance and strength training in patients with COPD. Chest. 2004;125:2036–2045
  47. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1179–1184
  48. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and functional limitation: data from the third National Health and Nutrition Examination. J Intern Med. 2003;254:540–547
  49. Couser JI, Guthmann R, Hamadeh MA, et al. Pulmonary rehabilitation improves exercise capacity in older elderly patients with COPD. Chest. 1995;107:730–734
  50. Troosters T, Casaburi R, Gosselink R, et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:19–38
  51. Xiao RP, Tomhave ED, Wang DJ, et al. Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest. 1998;101:1273–1282
  52. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–211
  53. Donato AJ, Lesniewski LA, Delp MD. Ageing and exercise training alter adrenergic vasomotor responses of rat skeletal muscle arterioles. J Physiol. 2007;579:115–125
  54. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: β-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005;2:475–483
  55. Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297–309
  56. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454–463
  57. Kubo H, Margulies KB, Piacentino V, et al. Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation. 2001;104:1012–1018
  58. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002;346:1357–1365
  59. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  60. Beta-Blocker Evaluation of Survival Trial Investigators . A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667
  61. Packer M, Coats AJ, Fowler MB, et al. Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  62. Dobre D, DeJongste MJ, Lucas C, et al. Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?. Br J Clin Pharmacol. 2007;63:356–364
  63. Krum H, Tonkin AM, Currie R, Djundjek R, Johnston CI. Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. Med J Aust. 2001 May 7;174(9):439–444
  64. Aranda JM, Krause-Steinrauf HJ, Greenberg BH, et al. Comparison of the beta blocker bucindolol in younger versus older patients with heart failure. Am J Cardiol. 2002;89:1322–1326
  65. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566
  66. Kotlyar E, Keogh AM, Macdonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21:1290–1295
  67. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37:1950–1956
  68. Heart Failure Society of America . Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10–38
  69. van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818–824

☆ Grant Support: American Sleep Medicine Foundation 21YI03, Irving Center for Clinical Research RR-0645, and American Lung Association CU-52259701 (S.J.). None of the authors receive direct financial support or have financial interests relevant to the subject of this manuscript.

PII: S0167-5273(07)02066-9

doi: 10.1016/j.ijcard.2007.12.001

International Journal of Cardiology
Volume 125, Issue 2 , Pages 209-215 , 10 April 2008

Article Tools

* Image Usage & Resolution